Catalyst Event
Hansoh Pharmaceutical Group Company Limited (3692) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
4/29/2026, 12:00:00 AM
Received two clinical trial approvals from China's NMPA for its self-developed Class 1 innovative drug, HS-10522 tablets, for the treatment of uncontrolled hypertension and primary aldosteronism.
Korean Translation
자체 개발 1등급 혁신 신약 HS-10522 정제에 대해 중국 국가약품감독관리국(NMPA)으로부터 두 건의 임상시험 승인을 획득함. 해당 임상시험은 조절되지 않는 고혈압 및 원발성 알도스테론증 치료를 위한 것임.
Related Recent Events
Livzon Pharmaceutical Group Inc (1513) · Other
Ex-dividend date for the final dividend of RMB 1.43 per share for the fiscal year 2025 on 2026-06-16, scheduled.
6/16/2026, 12:00:00 AM
Biocytogen Pharmaceuticals (Beijing) Co Ltd (2315) · Other
Annual General Meeting to be held on 2026-05-21 to review reports and approve plans; routine meetings typically have a 1-5% price impact, scheduled
5/21/2026, 12:00:00 AM
Shanghai Fosun Pharmaceutical (Group) Co Ltd (2196) · Other
An earnings briefing for the 2025 fiscal year and Q1 2026 results is scheduled for May 14, 2026. This routine communication event is estimated to have a price impact of at least 1% scheduled.
5/14/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
Caris Life Sciences to report first quarter 2026 financial results on May 7, 2026, scheduled.
5/7/2026, 12:00:00 AM
Guardant Health Inc (GH) · Earnings Release
Guardant Health is scheduled to release its Q1 2026 financial results after market close on May 7, 2026. Analysts forecast EPS of ($0.47) and revenue of $279.17 million. High importance estimated due to potential for significant volatility following earnings results, scheduled.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is scheduled to release its first quarter 2026 financial results after the market closes on May 7, 2026, with analysts forecasting revenue of approximately $617.5 million and an EPS of -$0.55; high importance is expected due to typical earnings volatility, scheduled.
5/7/2026, 12:00:00 AM